Milestone Scientific Delivers Stable Revenue and Reduces Operating Expenses by Over $500 Thousand in the Third Quarter of 2025
Milestone Scientific (NYSE: MLSS) reported third-quarter results for the period ended September 30, 2025, highlighting cost reductions and stable revenue.
Key Q3 figures: revenue ~$2.4M (vs $2.5M), gross profit ~$1.6M (70% of revenue), operating loss $(1.1)M (improved ~23% YoY), and net loss $(1.2)M, $(0.01) per share. Nine-month revenue was ~$6.9M (+5% YoY) with a nine-month net loss of $(4.6)M, $(0.06) per share. The company said it reduced operating expenses by over $500,000 in Q3 and reported cash and cash equivalents ~$1.3M and working capital ~$3.1M. Management emphasized operational transformation, international dental growth, and increasing medical disposables recurring revenue.
Milestone Scientific (NYSE: MLSS) ha riportato i risultati del terzo trimestre per il periodo terminato il 30 settembre 2025, evidenziando tagli ai costi e ricavi stabili.
Principali dati del Q3: fatturato ~2,4 milioni di dollari (contro 2,5 milioni), utile lordo ~1,6 milioni di dollari (70% del fatturato), perdita operativa (1,1) milioni di dollari (migliorata di ~23% anno su anno), e perdita netta (1,2) milioni, 0,01 dollari per azione. I nove mesi hanno registrato un fatturato di ~6,9 milioni (+5% YoY) con una perdita netta di nove mesi di (4,6) milioni, 0,06 dollari per azione. L'azienda ha dichiarato di aver ridotto le spese operative di oltre 500.000 dollari nel Q3 e ha riportato liquidi e equivalenti di cassa ~1,3 milioni di dollari e capitale circolante ~3,1 milioni di dollari. La direzione ha sottolineato la trasformazione operativa, la crescita internazionale nel settore odontoiatrico e l'aumento del reddito ricorrente da dispositivi medici.
Milestone Scientific (NYSE: MLSS) informó los resultados del tercer trimestre para el periodo terminado el 30 de septiembre de 2025, destacando reducciones de costos y ingresos estables.
Principales cifras del Q3: ingresos ~2,4 millones de USD (frente a 2,5 millones), beneficio bruto ~1,6 millones (70% de los ingresos), pérdida operativa (1,1) millones (mejorada ~23% interanual), y pérdida neta (1,2) millones, 0,01 USD por acción. Los ingresos de los nueve meses fueron ~6,9 millones (+5% interanual) con una pérdida neta de nueve meses de (4,6) millones, 0,06 USD por acción. La empresa dijo haber reducido los gastos operativos en más de 500,000 durante el Q3 y reportó efectivo y equivalentes ~1,3 millones y capital de trabajo ~3,1 millones. La dirección enfatizó la transformación operativa, el crecimiento dental internacional y el aumento de ingresos recurrentes de dispositivos médicos.
밀스톤 사이언티픽(NYSE: MLSS)가 2025년 9월 30일 종료된 기간의 3분기 실적을 발표하며 비용 절감과 매출의 안정성을 강조했습니다.
Q3 주요 수치: 매출 약 240만 달러 (2,500,000 달러 대비), 총이익 약 160만 달러 (매출의 70%), 영업손실 110만 달러 (전년 동기 대비 약 23% 개선), 그리고 순손실 120만 달러, 주당 0.01달러입니다. 9개월 매출은 약 690만 달러 (+전년동기 대비 5%)였으며 9개월 순손실은 (460만 달러), 주당 0.06달러였습니다. 회사는 Q3에 영업비를 50만 달러 이상 절감했고 현금 및 현금성자산 약 130만 달러, 운전자본 약 310만 달러를 보고했습니다. 경영진은 운영 혁신, 국제 치과 성장, 의료 소모품의 재발매 수익 증가를 강조했습니다.
Milestone Scientific (NYSE: MLSS) a publié ses résultats du troisième trimestre pour la période se terminant le 30 septembre 2025, en mettant en avant des réductions de coûts et des revenus stables.
Chiffres clés du T3 : chiffre d'affaires ~2,4 M$ (contre 2,5 M$), bénéfice brut ~1,6 M$ (70% du chiffre d'affaires), perte opérationnelle (1,1) M$ (améliorée d'environ 23% en glissement annuel), et perte nette (1,2) M$, 0,01 $ par action. Le chiffre d'affaires sur neuf mois était ~6,9 M$ (+5% YoY) avec une perte nette sur neuf mois de (4,6) M$, 0,06 $ par action. La société a indiqué avoir réduit les dépenses opérationnelles de plus de 500 000 $ au T3 et a signalé liquidités et équivalents ~1,3 M$ et fonds de roulement ~3,1 M$. La direction a mis l'accent sur la transformation opérationnelle, la croissance dentaire internationale et l'augmentation des revenus récurrents des dispositifs médicaux.
Milestone Scientific (NYSE: MLSS) berichtete über die Ergebnisse des dritten Quartals für den Zeitraum bis zum 30. September 2025 und hob Kostenreduktionen sowie stabile Umsätze hervor.
Schlüsseldaten Q3: Umsatz ca. 2,4 Mio. USD (gegenüber 2,5 Mio. USD), roher Gewinn ca. 1,6 Mio. USD (70% des Umsatzes), operativer Verlust (1,1) Mio. USD (verbessert um ca. 23% YoY), und niedrige Verlustnetto (1,2) Mio. USD, 0,01 USD je Aktie. Neunmonatsumsatz ~6,9 Mio. USD (+5% YoY) mit einem Neunmonatsverlust von (4,6) Mio. USD, 0,06 USD pro Aktie. Das Unternehmen sagte, es habe die operativen Ausgaben um über 500.000 USD im Q3 reduziert und berichtete Barbestand und Baräquivalente ~1,3 Mio. USD und Working Capital ~3,1 Mio. USD. Das Management hob die operative Transformation, das internationale Wachstum im Dentalbereich und die steigenden wiederkehrenden Einnahmen aus medizinischen Verbrauchsmaterialien hervor.
Milestone Scientific (NYSE: MLSS) أبلغت عن نتائج الربع الثالث للفترة المنتهية في 30 سبتمبر 2025، مع إبراز خفض التكاليف وإيرادات مستقرة.
أهم أرقام الربع الثالث: الإيرادات حوالي 2.4 مليون دولار (مقابل 2.5 مليون دولار)، الربح الإجمالي حوالي 1.6 مليون دولار (70% من الإيرادات), خسارة تشغيلية 1.1 مليون دولار (تحسن بنحو 23% سنوياً)، وخسارة صافية 1.2 مليون دولار، 0.01 دولار للسهم. كانت إيرادات الأشهر التسعة حوالي 6.9 مليون دولار (+5% سنوياً) مع خسارة صافية لمدة تسعة أشهر قدرها (4.6) مليون دولار، 0.06 دولار للسهم. قالت الشركة إنها خفضت النفقات التشغيلية بأكثر من 500,000 دولار في الربع الثالث وأبلغت عن النقد والنقد المعادل ~1.3 مليون دولار ورأس المال العامل ~3.1 مليون دولار. شددت الإدارة على التحول التشغيلي، ونمو الأسنان الدولية، وزيادة الإيرادات المتكررة من المستلزمات الطبية.
- Operating expenses reduced by over $500,000 in Q3 2025
- Operating loss improved by ~$0.3M (23%) in Q3 2025
- Nine-month revenue rose ~5% to ~$6.9M through Sept 30, 2025
- Q3 gross profit of ~$1.6M (70% of revenue)
- Q3 revenue declined to ~$2.4M from $2.5M year‑ago quarter
- Nine‑month net loss widened to $(4.6)M from $(2.7)M year‑ago
- Cash and cash equivalents were low at ~$1.3M as of Sept 30, 2025
- Gross margin slipped from 73% to 70% in Q3 2025
Insights
Mixed quarter: cost cuts improved operating results but net losses persist and cash remains limited.
Milestone Scientific reported near‑term revenue stability with quarterly sales of approximately
Liquidity and cumulative results are material constraints: net loss widened on a nine‑month basis to
Watch for execution milestones over the next 3–12 months: trends in quarterly revenue (domestic dental vs international dental and medical recurring sales), further SG&A reductions, any updates on Medicare and commercial reimbursement, and cash‑management actions before the next quarterly report.
Company outlines continued progress executing operational transformation and growth strategy across its dental and medical segments
ROSELAND, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today announced financial results and provided a business update for the third quarter ended September 30, 2025, highlighting continued progress on the Company’s transformation and growth initiatives.
Eric Hines, Chief Executive Officer of Milestone Scientific, stated, “During the third quarter, we made measurable progress executing our plan to build a leaner, more focused organization capable of sustained growth and improved profitability. Through disciplined cost management and operational restructuring, we reduced third-quarter operating expenses by over half a million dollars compared to the same period last year. At the same time, we delivered stable revenue performance while continuing to strengthen our underlying business fundamentals.”
“Within our dental segment, we continued to expand our direct sales programs in North America and continued securing new international registrations for our STA® Single Tooth Anesthesia System. We also enhanced our omnichannel digital marketing strategy to drive broader brand visibility and recurring e-commerce sales. On the medical side, we are encouraged by growing utilization and recurring revenue from CompuFlo® disposables, as well as increasing interest from hospitals and international distributors.”
“In parallel, we continue to advance our reimbursement strategy for CompuFlo®, building on recent progress in securing Medicare payment-rate assignments and expanding commercial coverage. These developments are key enablers for broader adoption in hospitals and pain-management settings. As we expand our institutional presence and align with payers, we believe reimbursement access will play an important role in driving the next phase of medical segment growth.”
“Our operational transformation is well underway. We have strengthened our sales infrastructure, improved organizational alignment, and are prioritizing initiatives with the highest near-term return potential. Looking ahead, we expect these actions to translate into improved margins, continued revenue stability, and long-term value creation for our shareholders,” concluded Hines.
Financial Results for the Three and Nine Months Ended September 30, 2025
For the three months ended September 30, 2025 and 2024, revenues were approximately
For the nine months ended September 30, 2025 and 2024, revenues were approximately
As of September 30, 2025, the Company reported cash and cash equivalents of approximately
Conference Call
Milestone Scientific’s executive management team will host a conference call on Friday, November 14, 2025 at 8:30 AM Eastern Time to discuss the Company’s financial results for the third quarter ended September 30, 2025, as well as the Company’s corporate progress and other developments.
The conference call will be available via telephone by dialing toll free 888-506-0062 for U.S. callers or +1 973-528-0011 for international callers and by entering the access code: 164353. A webcast and replay of the call may be accessed at Webcast URL: https://www.webcaster5.com/Webcast/Page/2306/53250.
An audio replay of the call will be available through Friday, November 28, 2025, and can be accessed by dialing 877-481-4010 for U.S. callers or +1 919-882-2331 for international callers and by entering the access code: 53250.
About Milestone Scientific Inc.
Milestone Scientific Inc. (MLSS), a technology focused medical research and development company that patents, designs and develops innovative injection technologies and instruments for medical and dental applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology® instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the MLSS brand video or visit milestonescientific.com.
Safe Harbor Statement
This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2024. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contact:
Crescendo Communications, LLC
Email: mlss@crescendo-ir.com
Tel: 212-671-1020
(tables follow)
| MILESTONE SCIENTIFIC AND SUBSIDIARIES | ||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||||||
| (UNAUDITED) | ||||||
| September 30, 2025 | December 31, 2024 | |||||
| ASSETS | ||||||
| Current assets: | ||||||
| Cash and cash equivalents | $ | 1,345,301 | $ | 3,258,058 | ||
| Accounts receivable, net of allowance for credit losses of | 706,924 | 475,376 | ||||
| Accounts receivable, related party | 9,612 | - | ||||
| Prepaid expenses and other current assets | 506,574 | 564,645 | ||||
| Inventories | 4,126,988 | 3,713,215 | ||||
| Advances on contracts | 1,414,702 | 1,275,260 | ||||
| Total current assets | 8,110,101 | 9,286,554 | ||||
| Furniture, fixtures and equipment, net | 18,254 | 12,921 | ||||
| Intangibles, net | 96,039 | 148,404 | ||||
| Right of use assets finance lease | 59,228 | 67,201 | ||||
| Right of use assets operating lease | 178,251 | 257,842 | ||||
| Other assets | 24,150 | 24,150 | ||||
| Total assets | $ | 8,486,023 | $ | 9,797,072 | ||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||
| Current liabilities: | ||||||
| Accounts payable | $ | 2,012,867 | $ | 1,021,393 | ||
| Accounts payable, related party | 1,027,360 | 493,313 | ||||
| Accrued expenses and other payables | 1,176,773 | 1,796,319 | ||||
| Accrued expenses, related party | 665,890 | 304,293 | ||||
| Current portion of finance lease liabilities | 23,919 | 12,530 | ||||
| Current portion of operating lease liabilities | 126,722 | 116,279 | ||||
| Total current liabilities | 5,033,531 | 3,744,127 | ||||
| Non-current portion of finance lease liabilities | 34,170 | 54,672 | ||||
| Non-current portion of operating lease liabilities | 68,927 | 165,573 | ||||
| Convertible notes payable, related parties | 800,000 | - | ||||
| Total liabilities | $ | 5,936,628 | $ | 3,964,372 | ||
| Commitments and contingencies | ||||||
| Stockholders’ equity | ||||||
| Common stock, par value shares outstanding as of September 30, 2025; 78,047,798 shares issued and 78,014,465 shares outstanding as of December 31, 2024; | 78,592 | 78,048 | ||||
| Additional paid in capital | 136,067,080 | 134,719,274 | ||||
| Accumulated deficit | (132,684,761 | ) | (128,053,106 | ) | ||
| Treasury stock, at cost, 33,333 shares | (911,516 | ) | (911,516 | ) | ||
| Total Milestone Scientific, Inc. stockholders’ equity | 2,549,395 | 5,832,700 | ||||
| Total liabilities and stockholders’ equity | $ | 8,486,023 | $ | 9,797,072 | ||
| MILESTONE SCIENTIFIC AND SUBSIDIARIES | ||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||
| (UNAUDITED) | ||||||||||||
| Three Months Ended | Three Months Ended | Nine Months Ended | Nine Months Ended | |||||||||
| September 30, 2025 | September 30, 2024 | September 30, 2025 | September 30, 2024 | |||||||||
| Product sales, net | $ | 2,360,117 | $ | 2,513,805 | $ | 6,916,003 | $ | 6,616,414 | ||||
| Cost of products sold | 719,247 | 677,585 | 2,010,092 | 1,692,888 | ||||||||
| Gross profit | 1,640,870 | 1,836,220 | 4,905,911 | 4,923,526 | ||||||||
| Selling, general and administrative expenses | 2,739,011 | 3,064,769 | 9,026,691 | 8,968,226 | ||||||||
| Research and development expenses | 16,226 | 232,056 | 437,135 | 641,235 | ||||||||
| Depreciation and amortization expense | 20,104 | 8,574 | 59,040 | 28,735 | ||||||||
| Total operating expenses | 2,775,341 | 3,305,399 | 9,522,866 | 9,638,196 | ||||||||
| Loss from operations | (1,134,471 | ) | (1,469,179 | ) | (4,616,955 | ) | (4,714,670 | ) | ||||
| Interest (expense) income, net | (19,488 | ) | 8,008 | (14,700 | ) | 53,513 | ||||||
| Gain on sale of net operating losses | - | - | - | 1,983,095 | ||||||||
| Loss before provision for income taxes | (1,153,959 | ) | (1,461,171 | ) | (4,631,655 | ) | (2,678,062 | ) | ||||
| Provision for income taxes | - | - | - | - | ||||||||
| Net loss | (1,153,959 | ) | (1,461,171 | ) | (4,631,655 | ) | (2,678,062 | ) | ||||
| Net loss per share applicable to common stockholders— | ||||||||||||
| Basic and Diluted | (0.01 | ) | (0.02 | ) | (0.06 | ) | (0.03 | ) | ||||
| Weighted average shares outstanding and to be issued— | ||||||||||||
| Basic and diluted | 82,322,910 | 79,966,833 | 82,008,336 | 80,165,181 | ||||||||
FAQ
What were Milestone Scientific (MLSS) Q3 2025 revenues and EPS?
How much did Milestone Scientific (MLSS) reduce operating expenses in Q3 2025?
What is Milestone Scientific's (MLSS) nine‑month 2025 revenue and net loss through Sept 30?
How did Milestone Scientific's (MLSS) margins change in Q3 2025?
What cash and liquidity did Milestone Scientific (MLSS) report as of Sept 30, 2025?
What commercial progress did Milestone Scientific (MLSS) report for CompuFlo® and STA®?
